BIOMARIN PHARMACEUTICAL INC - Common Stock, par value $0.001 per share (BMRN)

Historical Holders from Q1 2014 to Q3 2025

Symbol: BMRN on Nasdaq
Type / Class: Equity / Common Stock, par value $0.001 per share
Shares outstanding: 193,539,047
All holders as of 30 Sep 2025: Q3 2025
Total 13F shares, excl. options: 179,351,054
Holdings value: $9,713,608,207
% of all portfolios: 0.009%
Number of holders: 568
Number of buys: 293
Number of sells: -270
Average buys %: +0%
Average sells %: -0%

Reported Shares, Excluding Options vs Price

Reported Value, Excluding Options

Total Investors

Significant Owners of BIOMARIN PHARMACEUTICAL INC - Common Stock, par value $0.001 per share (BMRN)

Filer	Ownership	Change %	Holdings Value	Net Change	Nb Shares	Change %	Reporting Name	Report Period
BlackRock, Inc.	10.8%		$1,298,658,873		20,620,179		BlackRock, Inc.	31 Mar 2025
PRIMECAP MANAGEMENT CO/CA/	8.24%		$906,812,938		15,795,383		PRIMECAP MANAGEMENT CO/CA/	30 Jun 2025
Capital Research Global Investors	4.8%	-28.6%	$576,308,252	-$241,913,549	9,150,655	-29.6%	Capital Research Global Investors	31 Mar 2025
VIKING GLOBAL INVESTORS LP	4.3%	-35%	$450,729,215	-$214,821,957	8,322,179	-32.3%	VIKING GLOBAL INVESTORS LP	30 Sep 2025

Institutional Holders of BIOMARIN PHARMACEUTICAL INC - Common Stock, par value $0.001 per share (BMRN)

Period	Reported Shares, Excl. Options	Value, Excl. Options	Change	Puts Notional Value	Calls Notional Value	Price	Investors
2025 Q3	179,351,054	$9,713,608,207	-$263,517,396	$54,004,558	$82,463,305	$54.16	568
2025 Q2	184,517,274	$10,145,314,583	+$90,429,124	$59,850,139	$72,095,295	$54.97	576
2025 Q1	181,117,177	$12,795,609,480	-$83,582,224	$64,523,160	$87,510,787	$70.69	576
2024 Q4	183,186,403	$12,041,547,200	+$135,391,046	$106,844,795	$131,205,466	$65.73	536
2024 Q3	180,328,429	$12,672,555,041	-$377,350,661	$87,292,787	$139,669,304	$70.29	545
2024 Q2	184,765,128	$15,210,183,330	-$88,804,857	$94,564,238	$130,863,609	$82.33	555
2024 Q1	186,676,383	$16,305,278,098	+$52,133,744	$150,868,173	$148,576,074	$87.34	550
2023 Q4	185,955,477	$17,930,401,770	+$422,069,685	$82,583,582	$143,909,250	$96.42	540
2023 Q3	181,505,269	$16,056,450,996	+$288,283,093	$60,060,224	$109,803,680	$88.48	513
2023 Q2	178,653,463	$15,494,286,845	-$55,787,524	$97,720,195	$109,149,360	$86.68	548
2023 Q1	179,051,547	$17,400,388,762	-$352,972,540	$101,936,296	$195,945,408	$97.24	544
2022 Q4	182,911,512	$18,940,963,403	+$57,088,463	$75,681,876	$119,655,733	$103.49	570
2022 Q3	182,236,184	$15,455,338,348	+$265,782,383	$67,100,000	$93,470,293	$84.77	535
2022 Q2	179,167,298	$14,847,543,178	+$141,628,422	$61,666,700	$45,988,504	$82.87	525
2022 Q1	177,887,694	$13,719,376,304	+$56,012,733	$58,588,000	$103,959,000	$77.1	543
2021 Q4	177,134,050	$15,645,638,303	+$125,285,951	$101,828,000	$143,209,000	$88.35	539
2021 Q3	175,999,345	$13,600,848,412	+$49,734,828	$110,606,635	$59,043,000	$77.29	498
2021 Q2	176,035,547	$14,685,174,801	-$129,382,414	$132,226,960	$82,079,944	$83.44	510
2021 Q1	177,743,163	$13,419,458,431	-$323,613,922	$150,147,015	$100,119,135	$75.51	513
2020 Q4	182,409,125	$15,984,411,685	+$294,129,377	$201,344,725	$257,976,984	$87.69	519
2020 Q3	179,647,602	$13,663,308,058	-$318,133,163	$125,383,000	$146,499,000	$76.08	487
2020 Q2	180,885,676	$22,304,634,235	+$749,303,824	$148,927,000	$189,174,000	$123.34	516
2020 Q1	176,765,627	$14,935,321,561	+$286,486,516	$88,024,000	$119,735,000	$84.5	489
2019 Q4	173,399,113	$14,656,072,034	+$53,952,753	$134,418,000	$142,995,000	$84.55	454
2019 Q3	173,803,512	$11,713,783,697	-$329,529,601	$98,670,000	$75,105,000	$67.4	427
2019 Q2	178,061,150	$15,246,971,937	+$229,169,981	$136,148,000	$97,404,000	$85.65	471
2019 Q1	178,407,022	$15,847,079,543	-$79,141,968	$134,523,000	$91,560,000	$88.83	475
2018 Q4	179,234,022	$15,261,762,453	-$186,785,701	$83,582,000	$126,234,000	$85.15	459
2018 Q3	180,913,922	$17,544,279,006	-$163,074,756	$101,256,000	$120,002,000	$96.97	449
2018 Q2	182,744,905	$17,212,623,295	+$242,791,323	$94,291,000	$159,174,000	$94.2	440
2018 Q1	180,119,807	$14,603,106,292	+$188,116,053	$90,231,000	$69,371,000	$81.07	421
2017 Q4	177,577,894	$15,832,679,554	+$224,283,938	$116,857,000	$191,212,000	$89.17	431
2017 Q3	174,774,741	$16,264,630,184	+$327,519,029	$68,984,000	$87,311,000	$93.07	407
2017 Q2	171,446,875	$15,566,292,229	+$225,362,433	$73,817,000	$59,489,000	$90.82	423
2017 Q1	169,058,166	$14,840,823,389	+$900,396,515	$65,492,000	$44,421,000	$87.78	411
2016 Q4	169,392,815	$14,033,179,313	+$56,824,379	$76,355,000	$61,363,000	$82.84	404
2016 Q3	168,245,764	$15,561,381,289	+$820,936,102	$103,948,000	$84,277,000	$92.52	419
2016 Q2	159,820,679	$12,448,675,606	-$243,125,240	$72,762,000	$73,630,000	$77.8	386
2016 Q1	162,459,664	$13,396,780,263	+$49,991,390	$74,692,000	$95,212,000	$82.48	379
2015 Q4	161,240,868	$16,892,503,727	+$165,350,997	$179,566,000	$217,444,000	$104.76	381
2015 Q3	159,382,647	$16,784,552,713	+$116,767,806	$166,722,000	$170,872,000	$105.32	386
2015 Q2	157,700,975	$21,572,249,632	+$147,538,663	$229,888,000	$225,592,000	$136.78	390
2015 Q1	156,515,480	$19,500,401,807	+$1,280,160,168	$190,697,000	$139,672,000	$124.62	374
2014 Q4	147,645,431	$13,350,128,993	+$129,533,927	$46,570,000	$90,468,000	$90.4	338
2014 Q3	147,667,828	$10,655,377,287	+$238,496,683	$27,452,000	$65,159,000	$72.16	312
2014 Q2	144,555,723	$8,993,046,726	-$244,244,682	$91,090,000	$119,661,000	$62.21	319
2014 Q1	148,047,218	$10,094,601,533	+$481,416,489	$122,993,000	$87,524,000	$68.21	309